港股创新药延续震荡，资金逆势布局恒生创新药ETF（520500）

Group 1 - The core viewpoint is that the Hong Kong innovative drug sector is experiencing fluctuations, but many institutions remain optimistic about its future performance, particularly regarding the globalization of domestic innovative drugs and the valuation reshaping opportunities it presents [1] - Zheshang Securities expresses confidence in the "Chinaization" of global innovative drugs, highlighting the potential for domestic innovative drugs to accelerate their globalization, especially in areas like dual antibodies and ADCs [1] - The upcoming 85th American Diabetes Association Scientific Sessions from June 20-23, 2025, in Chicago is expected to showcase several domestic pharmaceutical companies' latest research in GLP-1 drugs, which could serve as a catalyst for the Hong Kong innovative drug sector [1] Group 2 - The Hang Seng Innovative Drug Index (HSIDI.HI) consists of 40 high-growth innovative drug companies selected from the Hong Kong market, with a remarkable annual increase of 88.45% [2] - The Hang Seng Innovative Drug ETF (520500), managed by Huatai-PB Fund, is one of the first ETF managers in the mainland and has maintained an 18-year record of zero errors in ETF operations, providing diversified and high-quality index investment tools [2] - The Hang Seng Innovative Drug ETF is the only ETF tracking the Hang Seng Innovative Drug Index in the mainland, facilitating T+0 trading for investors looking to enter the Hong Kong innovative drug sector [1][2]